Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors

Tae Nakano-Tateno; Kheng Joe Lau; Justin Wang; Cailin McMahon; Yasuhiko Kawakami; Toru Tateno; Takako Araki

doi:10.3389/fendo.2021.624686

Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors

Tae Nakano-Tateno, Kheng Joe Lau, Justin Wang, Cailin McMahon, Yasuhiko Kawakami, Toru Tateno, Takako Araki

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life. Management can be challenging and often requires multimodal treatment. Current treatment options, including surgery, conventional medical therapies such as dopamine agonists, somatostatin receptor agonists and radiotherapy, often fail to inhibit pituitary tumor growth. Recently, anti-tumor effects of chemotherapeutic drugs such as Temozolomide, Capecitabine, and Everolimus, as well as peptide receptor radionuclide therapy on aggressive pituitary tumors have been increasingly investigated and yield mixed, although sometimes promising, outcomes. The purpose of this review is to provide thorough information on non-surgical medical therapies and their efficacies and used protocols for aggressive pituitary adenomas from pre-clinical level to clinical use.

Original language	English (US)
Article number	624686
Journal	Frontiers in Endocrinology
Volume	12
DOIs	https://doi.org/10.3389/fendo.2021.624686
State	Published - Mar 26 2021

Bibliographical note

Funding Information:
This study is supported by grants from the Graduate School, University of Minnesota (UMF0011528 to TA, Grant-in-Aid 212588 to TA), the University of Alberta (Start-up to TT), the University Hospital Foundation (Medical Research Competition 2019 to TT), and the US National Institutes of Health (AR064195 to YK).

Publisher Copyright:
© Copyright © 2021 Nakano-Tateno, Lau, Wang, McMahon, Kawakami, Tateno and Araki.

Keywords

CAPTEM
PRRT (Peptide Receptor Radionuclide Therapy)
Temozolomide
aggressive pituitary tumors
non-surgical therapy
pituitary carcinomas

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.3389/fendo.2021.624686

OpenUrl availability

Full text

Cite this

@article{1f45516edd2c4e67a7b34215af6d638c,

title = "Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors",

abstract = "Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life. Management can be challenging and often requires multimodal treatment. Current treatment options, including surgery, conventional medical therapies such as dopamine agonists, somatostatin receptor agonists and radiotherapy, often fail to inhibit pituitary tumor growth. Recently, anti-tumor effects of chemotherapeutic drugs such as Temozolomide, Capecitabine, and Everolimus, as well as peptide receptor radionuclide therapy on aggressive pituitary tumors have been increasingly investigated and yield mixed, although sometimes promising, outcomes. The purpose of this review is to provide thorough information on non-surgical medical therapies and their efficacies and used protocols for aggressive pituitary adenomas from pre-clinical level to clinical use.",

keywords = "CAPTEM, PRRT (Peptide Receptor Radionuclide Therapy), Temozolomide, aggressive pituitary tumors, non-surgical therapy, pituitary carcinomas",

author = "Tae Nakano-Tateno and Lau, {Kheng Joe} and Justin Wang and Cailin McMahon and Yasuhiko Kawakami and Toru Tateno and Takako Araki",

note = "Funding Information: This study is supported by grants from the Graduate School, University of Minnesota (UMF0011528 to TA, Grant-in-Aid 212588 to TA), the University of Alberta (Start-up to TT), the University Hospital Foundation (Medical Research Competition 2019 to TT), and the US National Institutes of Health (AR064195 to YK). Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Nakano-Tateno, Lau, Wang, McMahon, Kawakami, Tateno and Araki.",

year = "2021",

month = mar,

day = "26",

doi = "10.3389/fendo.2021.624686",

language = "English (US)",

volume = "12",

journal = "Frontiers in Endocrinology",

issn = "1664-2392",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors

AU - Nakano-Tateno, Tae

AU - Lau, Kheng Joe

AU - Wang, Justin

AU - McMahon, Cailin

AU - Kawakami, Yasuhiko

AU - Tateno, Toru

AU - Araki, Takako

N1 - Funding Information: This study is supported by grants from the Graduate School, University of Minnesota (UMF0011528 to TA, Grant-in-Aid 212588 to TA), the University of Alberta (Start-up to TT), the University Hospital Foundation (Medical Research Competition 2019 to TT), and the US National Institutes of Health (AR064195 to YK). Publisher Copyright: © Copyright © 2021 Nakano-Tateno, Lau, Wang, McMahon, Kawakami, Tateno and Araki.

PY - 2021/3/26

Y1 - 2021/3/26

N2 - Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life. Management can be challenging and often requires multimodal treatment. Current treatment options, including surgery, conventional medical therapies such as dopamine agonists, somatostatin receptor agonists and radiotherapy, often fail to inhibit pituitary tumor growth. Recently, anti-tumor effects of chemotherapeutic drugs such as Temozolomide, Capecitabine, and Everolimus, as well as peptide receptor radionuclide therapy on aggressive pituitary tumors have been increasingly investigated and yield mixed, although sometimes promising, outcomes. The purpose of this review is to provide thorough information on non-surgical medical therapies and their efficacies and used protocols for aggressive pituitary adenomas from pre-clinical level to clinical use.

AB - Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life. Management can be challenging and often requires multimodal treatment. Current treatment options, including surgery, conventional medical therapies such as dopamine agonists, somatostatin receptor agonists and radiotherapy, often fail to inhibit pituitary tumor growth. Recently, anti-tumor effects of chemotherapeutic drugs such as Temozolomide, Capecitabine, and Everolimus, as well as peptide receptor radionuclide therapy on aggressive pituitary tumors have been increasingly investigated and yield mixed, although sometimes promising, outcomes. The purpose of this review is to provide thorough information on non-surgical medical therapies and their efficacies and used protocols for aggressive pituitary adenomas from pre-clinical level to clinical use.

KW - CAPTEM

KW - PRRT (Peptide Receptor Radionuclide Therapy)

KW - Temozolomide

KW - aggressive pituitary tumors

KW - non-surgical therapy

KW - pituitary carcinomas

UR - http://www.scopus.com/inward/record.url?scp=85103878615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103878615&partnerID=8YFLogxK

U2 - 10.3389/fendo.2021.624686

DO - 10.3389/fendo.2021.624686

M3 - Review article

C2 - 33841328

AN - SCOPUS:85103878615

SN - 1664-2392

VL - 12

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

M1 - 624686

ER -

Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this